Search  in | Advanced
   Print  
Comments

 
IN THIS SECTION
Archive
 

This section contains comments that have been submitted to the government docket on issues of concern to the transfusion medicine and cellular therapies communities. Click on a link below to read current comments. For access to past comments, check our archive.

Comments to FDA on Proposed Rule on Informed Consent Elements – 2/25/10
Comments to FDA for Draft IND Guidance on HPC-Cs – 01/14/10
Comments to FDA on Draft Guidance on Blood Donor Suitability and Blood Safety and H1N1 Pandemic - 12-3-09
Comments to CMS on Proposed 2010 Outpatient Payments for Blood Products – 08/31/09
Comments to CMS on Proposed 2010 Outpatient Payments for Stem Cell Procedures – 08/28/09 (PDF)
AABB Commends CMS for Recognizing Blood Costs in Inpatient Market Basket - 6/30/09
Comments to FDA on Draft Guidance for Use of Serological Tests to Reduce Transmission Risk of T. cruzi Infection – 6/15/09
Comments to FDA on cGTP and Additional Requirements for Manufacturers of HCT/Ps – 4/14/09
Amended Comments to the FDA on SNIs and the National Drug Code – 4/6/09
Comments to FDA on Adverse Event Reporting in Flu Pandemic – 2/9/09 (PDF)
Comments to FDA on SNIs and the National Drug Code – 2/9/09 (PDF)
Comments to NRC on Security and Continued Use of Cesium-137 Chloride Sources – 10/13/08
Comments to CMS on Proposed Changes to the Hospital Outpatient Prospective Payment System and CY 2009 Rates – 9/2/08
Amicus Curiae Brief of ABC, AABB and ARC in Support of LifeSouth Community Blood Centers Inc. -  8/18/08 (PDF)
Comments to The Joint Commission on Blood Management Candidate Performance Measures – 8/19/08
Comments to FDA on Draft Guidance on Re-entry of Donors Deferred Due to Reactive Tests Results for Anti-HBc – 8/15/08
Summary of Draft Comments to be Submitted to TJC on Blood Management Performance Measures – 8/8/08
Comments to FDA on Draft Guidance on Considerations for Pancreatic Islet Cell Products – 8/8/08
Comments to the FDA on Proposed Rule on Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing – 8/1/08 (PDF)
AABB West Nile Virus Task Force Comments to FDA on Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus – 7/25/08
Comments to FDA on Draft Guidance for Certifications to Accompany Drug, Biological Product and Device Applications/Submissions – 6/6/08
Comments to FDA on Draft Guidance for Validation of RMM for Sterility Testing of Cellular and Gene Therapy Products – 5/9/08
Comments to AHRQ on the Proposed Regulations for the Patients Safety and Quality Improvement Act of 2005 – 4/14/08
Comment to FDA on the Report of the Subcommittee on Science and Technology – 2/4/08
Last modified on 3/1/2010 12:21:10 PM
What's New!
AABB Weekly Report - March 5, 2010
Details
National Hemovigilance Program Launches to Track Adverse Events Associated with Blood Transfusion
Details
AABB Statement on XMRV Task Force
Details
Updated Circular of Information for Cellular Therapy Products
Details
Association Bulletin #10-01 - Association Bulletin Listings
Details
Current U.S. Blood Supply is Adequate to Handle Demands Resulting from Earthquake in Haiti
Details
Emerging Infectious Disease Agents
Details
Study Highlights Implications Of Influenza Pandemics On Blood Supplies
Details
Cellular Therapies Subsections
Details
Association Bulletin #09-08 - ISBT 128 Conditional Accreditation Status
Details
AABB Launches Facebook Fan Page
Details